Ocular Tuberculosis Therapeutics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	333 Pages	Future Market Insights	July, 2022	FMARI18333930

Best Price Guarantee
Price	from $5,000
Length	333 Pages
Publisher	Future Market Insights
Published Date	July, 2022
SKU	FMARI18333930

Ocular Tuberculosis Therapeutics Market: Global Industry Analysis 2017-2021 and Opportunity Assessment 2022-2032

A recent market study published by FMI on Ocular Tuberculosis Therapeutics offers a global industry analysis for 2017-2021 and opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

By Treatment Type:

First line treatment
Rifampicin
Isoniazid
Ethambutol
Pyrazinamide
Second line treatment
Other

By End-User:

Hospital
Clinics
Ambulatory Surgical Centers

Report Chapters

Executive Summary

The executive summary of the Ocular Tuberculosis Therapeutics Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Ocular Tuberculosis Therapeutics.

Chapter 01 - Market Overview

Readers can find the detailed segmentation and definition of the Ocular Tuberculosis Therapeutics Market in this chapter, which will help to understand basic information about Ocular Tuberculosis Therapeutics. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Ocular Tuberculosis Therapeutics Market report.

Chapter 02 - Market Background

This chapter includes detailed analysis of the By Nature processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.

Chapter 03 - Global Ocular Tuberculosis Therapeutics Market Demand Analysis 2017-2021 and Forecast, 2022-2032

The chapter include historical market value (US$ XX Billion) analysis (2017-2021) and current and future market value (US$ 47225.2 Million) and volume (3.9 %) projections (2022-2032). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.

Chapter 04 - Global Ocular Tuberculosis Therapeutics Market - Pricing Analysis

Based on By Nature, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.

Chapter 05 - Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

Based on By Treatment Type, Ocular Tuberculosis Therapeutics Market is segmented into First line treatment, Rifampicin, Isoniazid, Ethambutol, Pyrazinamide, Second line treatment, Other. This section also offers market attractiveness analysis based on By Treatment Type. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Treatment Type.

Chapter 06 - Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By End-User

Based on By End-User, Ocular Tuberculosis Therapeutics Market is segmented into Hospital, Clinics, Ambulatory Surgical Centers. This section also offers market attractiveness analysis based on By End-User. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By End-User.

Chapter 07 - Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

Based on By Region, Ocular Tuberculosis Therapeutics Market is segmented into North America,Latin America,Europe,East Asia,South Asia & Pacific,Middle East & Africa. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.

Chapter 08 - North America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of the Ocular Tuberculosis Therapeutics in the North American Region, along with a country-wise assessment that includes the US and Canada. Readers can also find Regional trends, regulations, and market growth based on different segment and countries in the North America Region.

Chapter 09 - Latin America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of Ocular Tuberculosis Therapeutics in the Latin America Region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and Regional trends, which are impacting growth of the Ocular Tuberculosis Therapeutics Market in the Latin America Region.

Chapter 10 - Europe Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of Ocular Tuberculosis Therapeutics in the European Region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and Regional trends, which are impacting growth of the Ocular Tuberculosis Therapeutics Market in the Regional market.

Chapter 11 - East Asia Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of Ocular Tuberculosis Therapeutics in the East Asia Region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and Regional trends, which are impacting growth of the Ocular Tuberculosis Therapeutics Market in the Regional market.

Chapter 12 - South Asia Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of Ocular Tuberculosis Therapeutics in the South Asia Region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and Regional trends, which are impacting growth of the Ocular Tuberculosis Therapeutics Market in the Regional market.

Chapter 13 - Middle East and Africa Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of Ocular Tuberculosis Therapeutics in the MEA Region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and Regional trends, which are impacting growth of the Ocular Tuberculosis Therapeutics Market in the Regional market.

Chapter 14 - Key Countries Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter offers insights into how the Ocular Tuberculosis Therapeutics Market is expected to grow in major countries globally.

Chapter 15 - Market Structure Analysis- Global Assessment

This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.

Chapter 16 - Competition Deep Dive (Tentative List)

This chapter includes company overview, By Nature portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are AstraZeneca, Bayer HealthCare AG, Biological E, BioVersys, Cadila Pharmaceuticals, Concept Pharmaceuticals Ltd., Infectex, Johnson & Johnson, Labatec-Pharma SA, Lupin Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Maneesh Pharmaceuticals, Novartis, Otsuka Novel Products, Pfizer, Pharmasyntez, Sandoz, Sanofi, Sequella, Inc., Themis Medicare Ltd.

Chapter 17 - Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Ocular Tuberculosis Therapeutics report.

Chapter 18 - Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Ocular Tuberculosis Therapeutics Market.

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand-side Trends; 1.3. Supply-side Trends; 1.4. Technology Roadmap Analysis; 1.5. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations
3. Market Background: 3.1. Market Dynamics; 3.1.1. Drivers; 3.1.2. Restraints; 3.1.3. Opportunity; 3.1.4. Trends; 3.2. Scenario Forecast; 3.2.1. Demand in Optimistic Scenario; 3.2.2. Demand in Likely Scenario; 3.2.3. Demand in Conservative Scenario; 3.3. Opportunity Map Analysis; 3.4. Investment Feasibility Matrix; 3.5. PESTLE and Porter’s Analysis; 3.6. Regulatory Landscape; 3.6.1. By Key Regions; 3.6.2. By Key Countries; 3.7. Regional Parent Market Outlook
4. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032: 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021; 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032; 4.2.1. Y-o-Y Growth Trend Analysis; 4.2.2. Absolute $ Opportunity Analysis
5. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment: 5.1. Introduction / Key Findings; 5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2017-2021; 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032; 5.3.1. First line treatment; 5.3.1.1. Rifampicin; 5.3.1.2. Isoniazide; 5.3.1.3. Ethambutol; 5.3.1.4. Pyrazinamide; 5.3.2. Second line treatment; 5.3.2.1. Flouroquinolones; 5.3.2.2. Aminoglycosides; 5.3.2.3. Cycloserine; 5.3.2.4. Polypeptides; 5.3.2.5. p-Aminosalicylic Acid; 5.3.2.6. Thioamides; 5.3.3. Combination Therapy; 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2017-2021; 5.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032
6. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By end-user: 6.1. Introduction / Key Findings; 6.2. Historical Market Size Value (US$ Mn) Analysis By end-user, 2017-2021; 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By end-user, 2022-2032; 6.3.1. Hospital; 6.3.2. Clinics; 6.3.3. Ambulatory Surgical Centers; 6.4. Y-o-Y Growth Trend Analysis By end-user, 2017-2021; 6.5. Absolute $ Opportunity Analysis By end-user, 2022-2032
7. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region: 7.1. Introduction; 7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021; 7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032; 7.3.1. North America; 7.3.2. Latin America; 7.3.3. Europe; 7.3.4. Asia Pacific; 7.3.5. MEA; 7.4. Market Attractiveness Analysis By Region
8. North America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 8.2.1. By Country; 8.2.1.1. U.S.; 8.2.1.2. Canada; 8.2.2. By Treatment; 8.2.3. By end-user; 8.3. Market Attractiveness Analysis; 8.3.1. By Country; 8.3.2. By Treatment; 8.3.3. By end-user; 8.4. Key Takeaways
9. Latin America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 9.2.1. By Country; 9.2.1.1. Brazil; 9.2.1.2. Mexico; 9.2.1.3. Rest of Latin America; 9.2.2. By Treatment; 9.2.3. By end-user; 9.3. Market Attractiveness Analysis; 9.3.1. By Country; 9.3.2. By Treatment; 9.3.3. By end-user; 9.4. Key Takeaways
10. Europe Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 10.2.1. By Country; 10.2.1.1. Germany; 10.2.1.2. U.K.; 10.2.1.3. France; 10.2.1.4. Spain; 10.2.1.5. Italy; 10.2.1.6. Rest of Europe; 10.2.2. By Treatment; 10.2.3. By end-user; 10.3. Market Attractiveness Analysis; 10.3.1. By Country; 10.3.2. By Treatment; 10.3.3. By end-user; 10.4. Key Takeaways
11. Asia Pacific Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 11.2.1. By Country; 11.2.1.1. China; 11.2.1.2. Japan; 11.2.1.3. South Korea; 11.2.1.4. Malaysia; 11.2.1.5. Singapore; 11.2.1.6. Australia; 11.2.1.7. New Zealand; 11.2.1.8. Rest of APAC; 11.2.2. By Treatment; 11.2.3. By end-user; 11.3. Market Attractiveness Analysis; 11.3.1. By Country; 11.3.2. By Treatment; 11.3.3. By end-user; 11.4. Key Takeaways
12. MEA Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 12.2.1. By Country; 12.2.1.1. GCC Countries; 12.2.1.2. South Africa; 12.2.1.3. Israel; 12.2.1.4. Rest of MEA; 12.2.2. By Treatment; 12.2.3. By end-user; 12.3. Market Attractiveness Analysis; 12.3.1. By Country; 12.3.2. By Treatment; 12.3.3. By end-user; 12.4. Key Takeaways
13. Key Countries Ocular Tuberculosis Therapeutics Market Analysis: 13.1. U.S.; 13.1.1. Pricing Analysis; 13.1.2. Market Share Analysis, 2021; 13.1.2.1. By Treatment; 13.1.2.2. By end-user; 13.2. Canada; 13.2.1. Pricing Analysis; 13.2.2. Market Share Analysis, 2021; 13.2.2.1. By Treatment; 13.2.2.2. By end-user; 13.3. Brazil; 13.3.1. Pricing Analysis; 13.3.2. Market Share Analysis, 2021; 13.3.2.1. By Treatment; 13.3.2.2. By end-user; 13.4. Mexico; 13.4.1. Pricing Analysis; 13.4.2. Market Share Analysis, 2021; 13.4.2.1. By Treatment; 13.4.2.2. By end-user; 13.5. Germany; 13.5.1. Pricing Analysis; 13.5.2. Market Share Analysis, 2021; 13.5.2.1. By Treatment; 13.5.2.2. By end-user; 13.6. U.K.; 13.6.1. Pricing Analysis; 13.6.2. Market Share Analysis, 2021; 13.6.2.1. By Treatment; 13.6.2.2. By end-user; 13.7. France; 13.7.1. Pricing Analysis; 13.7.2. Market Share Analysis, 2021; 13.7.2.1. By Treatment; 13.7.2.2. By end-user; 13.8. Spain; 13.8.1. Pricing Analysis; 13.8.2. Market Share Analysis, 2021; 13.8.2.1. By Treatment; 13.8.2.2. By end-user; 13.9. Italy; 13.9.1. Pricing Analysis; 13.9.2. Market Share Analysis, 2021; 13.9.2.1. By Treatment; 13.9.2.2. By end-user; 13.10. China; 13.10.1. Pricing Analysis; 13.10.2. Market Share Analysis, 2021; 13.10.2.1. By Treatment; 13.10.2.2. By end-user; 13.11. Japan; 13.11.1. Pricing Analysis; 13.11.2. Market Share Analysis, 2021; 13.11.2.1. By Treatment; 13.11.2.2. By end-user; 13.12. South Korea; 13.12.1. Pricing Analysis; 13.12.2. Market Share Analysis, 2021; 13.12.2.1. By Treatment; 13.12.2.2. By end-user; 13.13. Malaysia; 13.13.1. Pricing Analysis; 13.13.2. Market Share Analysis, 2021; 13.13.2.1. By Treatment; 13.13.2.2. By end-user; 13.14. Singapore; 13.14.1. Pricing Analysis; 13.14.2. Market Share Analysis, 2021; 13.14.2.1. By Treatment; 13.14.2.2. By end-user; 13.15. Australia; 13.15.1. Pricing Analysis; 13.15.2. Market Share Analysis, 2021; 13.15.2.1. By Treatment; 13.15.2.2. By end-user; 13.16. New Zealand; 13.16.1. Pricing Analysis; 13.16.2. Market Share Analysis, 2021; 13.16.2.1. By Treatment; 13.16.2.2. By end-user; 13.17. GCC Countries; 13.17.1. Pricing Analysis; 13.17.2. Market Share Analysis, 2021; 13.17.2.1. By Treatment; 13.17.2.2. By end-user; 13.18. South Africa; 13.18.1. Pricing Analysis; 13.18.2. Market Share Analysis, 2021; 13.18.2.1. By Treatment; 13.18.2.2. By end-user; 13.19. Israel; 13.19.1. Pricing Analysis; 13.19.2. Market Share Analysis, 2021; 13.19.2.1. By Treatment; 13.19.2.2. By end-user
14. Market Structure Analysis: 14.1. Competition Dashboard; 14.2. Competition Benchmarking; 14.3. Market Share Analysis of Top Players; 14.3.1. By Regional; 14.3.2. By Treatment; 14.3.3. By end-user
15. Competition Analysis: 15.1. Competition Deep Dive; 15.1.1. AstraZeneca; 15.1.1.1. Overview; 15.1.1.2. Product Portfolio; 15.1.1.3. Profitability by Market Segments; 15.1.1.4. Sales Footprint; 15.1.1.5. Strategy Overview; 15.1.1.5.1. Marketing Strategy; 15.1.2. Bayer HealthCare AG; 15.1.2.1. Overview; 15.1.2.2. Product Portfolio; 15.1.2.3. Profitability by Market Segments; 15.1.2.4. Sales Footprint; 15.1.2.5. Strategy Overview; 15.1.2.5.1. Marketing Strategy; 15.1.3. Biological E; 15.1.3.1. Overview; 15.1.3.2. Product Portfolio; 15.1.3.3. Profitability by Market Segments; 15.1.3.4. Sales Footprint; 15.1.3.5. Strategy Overview; 15.1.3.5.1. Marketing Strategy; 15.1.4. BioVersys; 15.1.4.1. Overview; 15.1.4.2. Product Portfolio; 15.1.4.3. Profitability by Market Segments; 15.1.4.4. Sales Footprint; 15.1.4.5. Strategy Overview; 15.1.4.5.1. Marketing Strategy; 15.1.5. Cadila Pharmaceuticals; 15.1.5.1. Overview; 15.1.5.2. Product Portfolio; 15.1.5.3. Profitability by Market Segments; 15.1.5.4. Sales Footprint; 15.1.5.5. Strategy Overview; 15.1.5.5.1. Marketing Strategy; 15.1.6. Concept Pharmaceuticals Ltd.; 15.1.6.1. Overview; 15.1.6.2. Product Portfolio; 15.1.6.3. Profitability by Market Segments; 15.1.6.4. Sales Footprint; 15.1.6.5. Strategy Overview; 15.1.6.5.1. Marketing Strategy; 15.1.7. Infectex, Johnson & Johnson; 15.1.7.1. Overview; 15.1.7.2. Product Portfolio; 15.1.7.3. Profitability by Market Segments; 15.1.7.4. Sales Footprint; 15.1.7.5. Strategy Overview; 15.1.7.5.1. Marketing Strategy; 15.1.8. Labatec-Pharma SA; 15.1.8.1. Overview; 15.1.8.2. Product Portfolio; 15.1.8.3. Profitability by Market Segments; 15.1.8.4. Sales Footprint; 15.1.8.5. Strategy Overview; 15.1.8.5.1. Marketing Strategy; 15.1.9. Lupin Pharmaceuticals Inc.; 15.1.9.1. Overview; 15.1.9.2. Product Portfolio; 15.1.9.3. Profitability by Market Segments; 15.1.9.4. Sales Footprint; 15.1.9.5. Strategy Overview; 15.1.9.5.1. Marketing Strategy; 15.1.10. Macleods Pharmaceuticals Ltd.; 15.1.10.1. Overview; 15.1.10.2. Product Portfolio; 15.1.10.3. Profitability by Market Segments; 15.1.10.4. Sales Footprint; 15.1.10.5. Strategy Overview; 15.1.10.5.1. Marketing Strategy; 15.1.11. Maneesh Pharmaceuticals; 15.1.11.1. Overview; 15.1.11.2. Product Portfolio; 15.1.11.3. Profitability by Market Segments; 15.1.11.4. Sales Footprint; 15.1.11.5. Strategy Overview; 15.1.11.5.1. Marketing Strategy; 15.1.12. Novartis; 15.1.12.1. Overview; 15.1.12.2. Product Portfolio; 15.1.12.3. Profitability by Market Segments; 15.1.12.4. Sales Footprint; 15.1.12.5. Strategy Overview; 15.1.12.5.1. Marketing Strategy; 15.1.13. Otsuka Novel Products; 15.1.13.1. Overview; 15.1.13.2. Product Portfolio; 15.1.13.3. Profitability by Market Segments; 15.1.13.4. Sales Footprint; 15.1.13.5. Strategy Overview; 15.1.13.5.1. Marketing Strategy; 15.1.14. Pfizer; 15.1.14.1. Overview; 15.1.14.2. Product Portfolio; 15.1.14.3. Profitability by Market Segments; 15.1.14.4. Sales Footprint; 15.1.14.5. Strategy Overview; 15.1.14.5.1. Marketing Strategy; 15.1.15. Pharmasyntez; 15.1.15.1. Overview; 15.1.15.2. Product Portfolio; 15.1.15.3. Profitability by Market Segments; 15.1.15.4. Sales Footprint; 15.1.15.5. Strategy Overview; 15.1.15.5.1. Marketing Strategy; 15.1.16. Sandoz; 15.1.16.1. Overview; 15.1.16.2. Product Portfolio; 15.1.16.3. Profitability by Market Segments; 15.1.16.4. Sales Footprint; 15.1.16.5. Strategy Overview; 15.1.16.5.1. Marketing Strategy; 15.1.17. Sanofi; 15.1.17.1. Overview; 15.1.17.2. Product Portfolio; 15.1.17.3. Profitability by Market Segments; 15.1.17.4. Sales Footprint; 15.1.17.5. Strategy Overview; 15.1.17.5.1. Marketing Strategy; 15.1.18. Sequella, Inc.; 15.1.18.1. Overview; 15.1.18.2. Product Portfolio; 15.1.18.3. Profitability by Market Segments; 15.1.18.4. Sales Footprint; 15.1.18.5. Strategy Overview; 15.1.18.5.1. Marketing Strategy; 15.1.19. Themis Medicare Ltd.; 15.1.19.1. Overview; 15.1.19.2. Product Portfolio; 15.1.19.3. Profitability by Market Segments; 15.1.19.4. Sales Footprint; 15.1.19.5. Strategy Overview; 15.1.19.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology